Ascletis bets on once-monthly ASC36 to fight obesity
October 30, 2025 | 15:15
Ascletis Pharma Inc. announces that it has selected ASC36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor agonist, as a clinical development candidate.
Ascletis ASC30 U.S. Phase IIa Obesity Study Reaches Full Enrollment
October 20, 2025 | 16:13
Once-monthly depot formulation targets adherence barriers; investigators will now examine whether small-molecule GLP-1 agonists can match peptide efficacy without cold-chain burden.
Ascletis ASC35 2025: Once-Monthly GLP-1/GIP Dual Agonist Selected for Clinic
October 13, 2025 | 16:17
Obesity and diabetes candidate targets fifteen per cent weight loss, handing pharma blogs ASC35 keywords and Phase I sites.
Mobile Version